Research Analysts Offer Predictions for ABEO FY2025 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Thursday, November 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will earn $1.15 per share for the year, down from their previous forecast of $1.41. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Cantor Fitzgerald also issued estimates for Abeona Therapeutics’ FY2026 earnings at ($0.28) EPS.

Several other analysts have also recently commented on the company. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings cut shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Oppenheimer upped their target price on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock opened at $4.48 on Monday. The stock has a market capitalization of $242.78 million, a P/E ratio of 6.40 and a beta of 1.45. The business has a 50 day simple moving average of $5.25 and a two-hundred day simple moving average of $5.94. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.54. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth approximately $25,000. Legal & General Group Plc acquired a new position in Abeona Therapeutics in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new position in Abeona Therapeutics in the third quarter worth approximately $37,000. Legato Capital Management LLC acquired a new stake in Abeona Therapeutics during the third quarter worth $57,000. Finally, Riverwater Partners LLC purchased a new stake in Abeona Therapeutics in the second quarter valued at $62,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling

In related news, CFO Joseph Walter Vazzano sold 9,035 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $5.39, for a total value of $48,698.65. Following the completion of the sale, the chief financial officer owned 453,631 shares of the company’s stock, valued at approximately $2,445,071.09. This represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mark Alvino sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $4.74, for a total transaction of $71,100.00. Following the sale, the director owned 62,252 shares of the company’s stock, valued at approximately $295,074.48. The trade was a 19.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 78,612 shares of company stock valued at $410,271 over the last 90 days. Insiders own 6.90% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.